Sonderforschungsbereich 824: Central project for histopathology, immunohistochemistry and analytical microscopy) represents an interdisciplinary consortium which aims at the development of novel imaging technologies for the selection and monitoring of cancer therapy as an important support for personalized medicine. Z2, the central unit for comparative morphomolecular pathology and computational validation, provides integration, registration and quantification of data obtained from both macroscopic and (sub-)cellular in-vivo as well as ex-vivo imaging modalities with tissue-based morphomolecular readouts as the basis for the development and establishment of personalized medicine. In order to develop novel imaging technologies, co-annotation and validation of image data acquired by preclinical or diagnostic imaging platforms via tissue based quantitative morphomolecular methods is crucial. Light sheet microscopy will continue to close the gap between 3D data acquired by in-vivo imaging and 2D histological slices especially focusing on tumor vascularization. The Multimodal ImagiNg Data Flow StUdy Lab (MINDFUL) is a central system for data management in preclinical studies developed within SFB824. Continuing the close collaboration of pathology, computer sciences and basic as well as translational researchers from SFB824 will allow the Z2 to develop and subsequently provide a broad variety of registration and analysis tools for joint imaging and tissue based image standardization and quantification.
The goal of the BFS Project: ImmunoProfiling using Neuronal Networks (IPN2) is to develop a method based on neuronal networks and recent advances in Deep Learning to allow characterization of a patient's tumor as ″hot″ or ″cold″ tumor depending on the identified ImmunoProfile. Recent research has shown that many tumors are infiltrated by immuno-competent cells, as well as that the amount, type and location of the infiltrated lymph nodes in primary tumors provide valuable prognostic information. In contrast to a ″cold tumor″, a ″hot tumor″ is characterized by an active immune system which the tumor has identified as threat. This identification provides the basis for selecting the therapy best suitable for the individual patient.
|K. Westenfelder, B. Lentes, J. Rackerseder, N. Navab, J. Gschwend, M. Eiber, C. R. Maurer, Jr.
Gallium-68 HBED-CC-PSMA Positron Emission Tomography/Magnetic Resonance Imaging for Prostate Fusion Biopsy
Clinical genitourinary cancer, August 2018, Volume 16, Issue 4, Pages 245-247 (bib)
|B. Busam, P. Ruhkamp, S. Virga, B. Lentes, J. Rackerseder, N. Navab, C. Hennersperger
Markerless Inside-Out Tracking for 3D Ultrasound Compounding
International Conference on Medical Image Computing and Computer Assisted Interventions (MICCAI), Point-of-Care Ultrasound, Granada, Spain, September 2018 (bib)
|O. Zettinig, J. Rackerseder, B. Lentes, T. Maurer, K. Westenfelder, M. Eiber, B. Frisch, N. Navab
Preconditioned Intensity-Based Prostate Registration using Statistical Deformation Models
IEEE International Symposium on Biomedical Imaging (ISBI), Melbourne, April 2017. (bib)